Tepotinib (Indications)
Non-Small Cell Lung Cancer (NSCLC): Specifically approved for patients with metastatic NSCLC who have MET exon 14 skipping mutations. This genetic alteration is present in a small subset of NSCLC patients and is associated with poor prognosis.